Drug Discovery Weekly — May 12, 2026
The FDA agreed to reconsider Ebvallo, a rare-disease T-cell therapy from Pierre Fabre and Atara Biotherapeutics, after a surprise earlier rejection — with the agency now signaling a single completed trial may suffice for approval. On the deals front, two major transactions reshuffled the industry landscape: Angelini Pharma announced a $4.1 billion acquisition of Catalyst Pharmaceuticals, and Sun Pharma struck an $11.75 billion deal to acquire Organon. Lilly and Gilead continued to lead 2026's M&A surge, with deal volume substantially outpacing last year according to BioPharma Dive.
Drug Discovery Weekly — May 12, 2026
FDA & Regulatory Decisions
Ebvallo (Pierre Fabre / Atara Biotherapeutics) — Regulatory Reconsideration
- Indication: Rare disease (EBV-positive post-transplant lymphoproliferative disease)
- Significance: After an earlier surprise rejection, Pierre Fabre Pharmaceuticals and Atara Biotherapeutics met with FDA officials in late April. The agency agreed that their already-completed, single-arm clinical trial could be sufficient for reconsideration — a potentially pivotal development in how the FDA evaluates rare-disease therapies with limited patient populations. This aligns with the broader FDA shift toward accepting single-study evidence for approval.
- Timeline: Resubmission process underway following the late-April meeting; no new PDUFA date disclosed yet.
Vyvgart (Argenx) — Expanded Label Approval (gMG)
- Indication: Generalized myasthenia gravis (gMG) — expanded label
- Significance: The expanded approval for Argenx's Vyvgart broadens the addressable patient population in gMG, reinforcing the drug's position as a cornerstone therapy in neuromuscular disease. The FDA is also evaluating the drug for systemic lupus erythematosus (SLE), with a decision expected by December 2026.
- Timeline: SLE decision expected December 2026.
Single-Study Approval Policy — FDA Regulatory Reform
- Indication: Applies broadly across new drug applications
- Significance: FDA officials Vinay Prasad and Martin Makary published a commentary detailing the agency's new framework requiring only one clinical study — rather than the traditional two — to approve new drugs and medical products. The policy formally accelerates a trend that had been building, and the Ebvallo reconsideration this week represents an early real-world test case. Critics note this raises questions about standards of evidence; proponents argue it eliminates redundant trials for products with compelling data.
- Timeline: Policy already in effect; June 2026 PDUFA calendar includes decisions on treatments for COVID-19, gout, nicotine dependence, severe hypertriglyceridemia, and thyroid eye disease.
Clinical Trial Milestones
No pivotal Phase 2/3 trial readouts published after May 5, 2026 were identified in this week's verified research results. The pipeline watch section below covers upcoming catalysts.
Pharma Deals & M&A
-
Acquisition: Angelini Pharma + Catalyst Pharmaceuticals — $4.1 billion (€3.5 billion). Italy-based Angelini Pharma entered a definitive agreement to acquire Catalyst Pharmaceuticals, marking its entry into the U.S. market. The deal consolidates Angelini's position in brain health and rare disease, adding Catalyst's portfolio of approved neuromuscular and neurological therapies. BioPharma Dive notes Catalyst is the fourth biotech acquired in May alone, putting 2026 on a faster M&A pace than any year since at least 2018.
-
Acquisition: Sun Pharma + Organon — $11.75 billion. Sun Pharma announced a landmark agreement to acquire Organon, which would vault the combined entity to the 7th-largest biosimilar player globally. The deal carries direct implications for biologic access in dermatology and other therapeutic areas. Lilly and Gilead are also cited as leading 2026's M&A boom, with activity concentrated in cancer and autoimmune disease.
AI & Computational Drug Discovery
-
Nature / BJC Reports: A review published in BJC Reports (Nature portfolio) assessed precision oncology in the AI era, finding that compounds identified through AI-assisted approaches have demonstrated acceptable safety profiles and measurable biological activity in humans — benchmarks the authors describe as "difficult to attain in oncology drug development." The study highlights AlphaFold's role in enabling structure-informed drug design for cancer-associated targets, and notes that early AI-designed biologics — including peptide therapeutics, antibodies, and mRNA-based candidates — are entering clinical evaluation, moving computational design "beyond theory into practice."
-
The Medicine Maker / Industry Trend: An April 2026 industry analysis in The Medicine Maker documented the accelerating pipeline of AI-designed biologics entering human trials, with multiple peptide and antibody candidates now in clinical evaluation. The piece underscores that computational design is proving its clinical utility across modalities — not just small molecules — as pharma companies race to integrate AI into earlier and earlier stages of drug design.
Pipeline Watch: Key Upcoming Catalysts
-
June 2026 (multiple dates): FDA PDUFA decisions expected for treatments targeting COVID-19, gout, nicotine dependence, severe hypertriglyceridemia, and thyroid eye disease — per the Rheumatology Advisor's June 2026 FDA decision tracker.
-
December 2026: Vyvgart (argenx) — FDA decision expected for systemic lupus erythematosus (SLE) indication, following recent approval of the CD20 antibody for lupus nephritis.
-
Ongoing — Q2 2026: Targeted Oncology flagged five key FDA oncology decisions in Q1/Q2 2026 for solid tumors and rare hematologic malignancies; specific PDUFA dates were not confirmed in available research.
Week in Context
This week crystallized two of the most consequential structural shifts reshaping drug development in 2026. First, the FDA's reversal on Ebvallo — combined with the agency's published policy requiring only a single clinical study for approval — signals a genuine philosophical reorientation at the agency. Under Commissioners Prasad and Makary, the FDA is explicitly trading some evidentiary redundancy for speed, betting that well-designed single trials, real-time monitoring pilots, and tighter post-market surveillance can compensate. For rare-disease developers in particular, this is transformative: the ability to rely on a completed single-arm trial dramatically changes the economics and feasibility of pursuing small patient populations.
The M&A environment is evolving in lockstep. With Angelini's $4.1B Catalyst deal and Sun Pharma's $11.75B Organon acquisition both closing within the same week, 2026 is cementing its status as a landmark dealmaking year. BioPharma Dive confirms deal pace is outrunning every year since at least 2018 — driven by patent cliff anxieties at large-cap pharma, attractively valued mid-cap biotechs, and a regulatory environment that is increasingly signaling faster paths to approval. Cancer and autoimmune disease remain the preferred strategic targets, reflecting where clinical and commercial confidence is highest.
The AI thread running through this week's news is subtler but equally significant. The clinical validation of AI-designed biologics — documented in BJC Reports and industry analyses — represents a maturation milestone. Early AI drug discovery was dominated by target identification and small-molecule optimization; the emergence of AI-designed peptides, antibodies, and mRNA candidates now entering human trials suggests the technology is expanding its footprint across modalities. As regulatory pathways shorten and deal activity intensifies, companies with credible AI-to-clinic pipelines are increasingly attractive acquisition targets — a dynamic likely to accelerate through the remainder of 2026.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
